The American Chamber of Commerce in Croatia (AmCham) raises concerns about the proposed changes to the rulebook on drug pricing, introduced without prior notice or stakeholder input. The proposal could jeopardize medicine availability, reduce profitability for manufacturers, and disrupt the healthcare system. AmCham recommends retaining current provisions on margins, reference countries, and pricing methodology. It calls for withdrawal of the proposal and the formation of a working group involving key healthcare stakeholders to ensure sustainable and transparent reform that protects both patients and the pharmaceutical market.